Why the study?
Arterial hypertension and type 2 diabetes pose a major public health burden in patients aged 65 years and older, prompting evaluation of the acceptability, clinical effectiveness, and cost-effectiveness of telemonitoring at the primary care level.
Does a mHealth telemonitoring intervention improve systolic blood pressure and HbA1c in elderly patients (≥65 years) with hypertension and type 2 diabetes?
Does a mHealth telemonitoring intervention improve systolic blood pressure and HbA1c in elderly patients (≥65 years) with hypertension and type 2 diabetes?
Answers are grounded in this paper and cite their sources.
This protocol outlines a planned multicenter randomized controlled pilot study to evaluate the clinical and cost-effectiveness of telemonitoring for elderly patients with hypertension and type 2 diabetes in primary care.
Introduction: Arterial hypertension (AH) and type 2 diabetes (T2D) represent a significant burden for the public health system, with an exceptionally high prevalence in patients aged ≥65 years. This study aims to test the acceptability, clinical effectiveness, and cost-effectiveness of telemonitoring in elderly patients with AH and T2D at the primary care level. Methods: A m ulti-centre, prospective, randomized, controlled t rial w ill be conducted. Patients a ged ≥ 65 y ears with AH and T2D will be randomized in a 1:1 proportion to a mHealth intervention or standard care group. Patients in the intervention group will measure their blood pressure (BP) twice weekly and blood glucose (BG) once monthly. The readings will be synchronously transmitted via a mobile application to the telemonitoring platform, where they will be reviewed by a general practitioner who will indicate changes in measurement regimen or carry out a teleconsultation. The primary endpoint will be a change in systolic BP (SBP) and glycated haemoglobin (HbA1c) relative to standard care up to 12 months after inclusion. Secondary endpoints will be a change in other observed clinical variables, quality-of-life indexes, and costs. Expected results: Telemonitoring will be an acceptable method of care associated with significant reductions in SBP and HbA1c levels and an increase in quality-of-life indexes in the intervention group. However, the cost-effectiveness threshold (incremental cost-effectiveness ratio below €25,000/quality-adjusted life year) might not be reached. Conclusion: This study will provide new evidence for scaling up telemonitoring network at the primary care level and modifying telemonitoring protocols to achieve the best clinical and cost-effective outcomes.
No takes yet. Share an insight, caveat, or question.
Mihevc et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: